Snyder M A, Bishop J M
Virology. 1984 Jul 30;136(2):375-86. doi: 10.1016/0042-6822(84)90174-0.
Previously (M.A. Snyder, J.M. Bishop, W.W. Colby, and A.D. Levinson, 1983, Cell 32, 891-901) a mutant was constructed in v-src in which the major phosphotyrosine site, tyr-416, was converted to phenylalanine. This mutant has now been examined both for tumorigenicity and a number of in vitro parameters relating to the transformed state and to the known properties of pp60v-src, the product of v-src. Mouse cells transformed by this mutant gene, which are called RSV-SF1, are tumorigenic only if tested in immunodeficient mice, whereas cells transformed by the wild-type parent are tumorigenic in either syngeneic or immunodeficient animals. When examined in vitro, RSV-SF1-transformed cells are virtually indistinguishable from cells transformed by wild-type pp60v-src. These findings raise the possibility that the protein kinase activity of pp60v-src may not be fully responsible for tumorigenesis by v-src, and moreover suggest that evasion of the host immune response is a necessary step in tumorigenesis by v-src.
先前(M.A. 斯奈德、J.M. 毕晓普、W.W. 科尔比和A.D. 莱文森,1983年,《细胞》第32卷,891 - 901页)在v-src中构建了一个突变体,其中主要的磷酸酪氨酸位点tyr-416被转化为苯丙氨酸。现在已经对该突变体的致瘤性以及一些与转化状态和v-src产物pp60v-src的已知特性相关的体外参数进行了检测。由这个突变基因转化的小鼠细胞,称为RSV-SF1,只有在免疫缺陷小鼠中进行测试时才具有致瘤性,而由野生型亲本转化的细胞在同基因或免疫缺陷动物中都具有致瘤性。在体外检测时,RSV-SF1转化的细胞与野生型pp60v-src转化的细胞几乎没有区别。这些发现增加了pp60v-src的蛋白激酶活性可能不完全负责v-src致瘤的可能性,而且表明逃避宿主免疫反应是v-src致瘤的必要步骤。